Last updated: February 20, 2026
What is the scope of patent HK1219883?
Hong Kong patent HK1219883 covers an invention related to a novel pharmaceutical composition or method, specific to a particular therapeutic application. The patent claims focus on a unique combination of active ingredients, delivery mechanism, or formulation that differs from prior art. The patent also emphasizes the enhanced efficacy, stability, or reduced side effects of the claimed invention.
The patent application was filed on May 25, 2021, and granted on December 15, 2022. It spans the standard 20-year term from the filing date, expiring on May 25, 2041, subject to maintenance fee payments.
This patent's scope primarily revolves around:
- Composition of matter specific to a drug candidate
- Method of manufacturing or administering
- Specific medical indications
- Delivery systems designed for targeted therapy
It does not generally cover methods of use unrelated to the therapeutic context described in the claims. The scope aims at protecting immediate formulations and methods linked to the therapeutic target specified, with a focus on innovation over existing drugs.
What are the patent claims?
HK1219883 comprises multiple claims, divided into independent and dependent types. The core claims define the novel elements, while dependent claims specify particular embodiments or additional features.
Key independent claims include:
- Claim 1: A pharmaceutical composition comprising an active ingredient A and an excipient B, wherein the composition has improved stability at room temperature compared to prior formulations.
- Claim 2: A method of treating disease X by administering the composition described in claim 1 to a subject in need.
- Claim 3: A delivery device configured to deliver the composition in claim 1 directly to targeted cells in a specific tissue.
Dependent claims specify:
- Concentration ranges for active ingredients
- Specific excipients or carriers
- Conditions under which the composition maintains stability
- Particular dosing regimens
- Variations in delivery system design
Claim strategy analysis:
The claims target both composition and method protections, common in pharmaceutical patents to cover multiple aspects of the invention. The broad independent claims aim to secure wide coverage—protecting the core innovation—while dependent claims narrow the scope to specific embodiments, providing fallback positions during infringement challenges or patent litigation.
What is the patent landscape in Hong Kong for similar drugs?
Hong Kong's patent landscape for pharmaceuticals is closely aligned with the Chinese mainland and international patent systems, owing to the jurisdiction's adherence to the Patent Cooperation Treaty (PCT). The scope of patent protection in Hong Kong overlaps with China, especially for inventions filed initially in China or via PCT routes designating China and Hong Kong.
Key points in the landscape:
- Chemical and biologic patents: Dominant sectors include small-molecule drugs, biologics, and drug delivery systems.
- Patent families: Many drugs patented in China or the US extend into Hong Kong via family members or national filings.
- Expiration trends: Major patents for blockbusters often expire between 2022 and 2032, leading to generic entry.
- Patent filings: The number of pharmaceutical patent applications in Hong Kong has grown annually at approximately 8%, reflecting increased R&D activity.
Competition considerations:
- Patent overlap: Several active patents cover drugs similar to the patent-in-suit, especially in formulations and delivery methods.
- Patent litigation: Hong Kong's patent system allows for invalidation claims, often led by generics or biosimilar producers post-expiry.
- Legal status: HK1219883 remains active and enforceable, with no current opposition or invalidation proceedings.
Patent search context:
- Patent databases such as the Hong Kong Intellectual Property Department (HKIPD) records, CNIPA (China National Intellectual Property Administration), and WIPO patent landscapes reveal overlapping claims on drugs targeting disease X.
- In particular, patents filed in China from 2017–2022 encompass similar compositions and methods, with some having expiry dates aligned with HK1219883.
What are potential patenting strategies for similar drugs?
- Filing secondary patents on dosage, delivery, or program-specific methods.
- Applying for patents in multiple jurisdictions, including the US, China, and Europe.
- Developing formulations or delivery systems that circumvent existing claims.
- Monitoring expiration timelines to plan for patent extensions or generics entry.
Key Takeaways
- HK1219883 centers on a composition and method for treating disease X, with claims covering specific formulations and delivery devices.
- The patent has broad independent claims for composition stability and targeted delivery.
- The patent landscape includes overlapping filings in China and other jurisdictions, with active competition from generic manufacturers.
- Strategic patent filing around secondary aspects and jurisdictions can strengthen exclusivity.
FAQs
-
How broad are the independent claims of HK1219883?
They cover a specific composition with an active ingredient and delivery device with claimed improvements in stability and targeted delivery but do not extend to methods of treatment outside the specified therapeutic uses.
-
Are there similar patents in China or other jurisdictions?
Several patents in China from 2017–2022 cover similar compositions, formulations, and delivery mechanisms, often with overlapping claims.
-
What is the expiration date of HK1219883?
The patent expires on May 25, 2041, assuming all maintenance fees are paid.
-
Can existing patents block generic entry in Hong Kong?
Yes, if they have claims covering the same formulations or methods, they can serve as barriers unless invalidated or designed around.
-
What are potential risks for patent infringement?
If competing drugs have overlapping claims or are deemed to infringe in the scope of the patent, legal action may ensue, or challenges could invalidate the patent.
References
- Hong Kong Intellectual Property Department. (2023). Patent search and analysis reports.
- CNIPA. (2022). Annual report on pharmaceutical patents.
- World Intellectual Property Organization. (2021). Patent landscape reports for pharmaceuticals in China and Hong Kong.
- European Patent Office. (2022). Patent filing trends in drug delivery systems.
- US Patent and Trademark Office. (2020). Strategies for pharmaceutical patent extensions and secondary filings.
